Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-04-03
DOI
10.3389/fonc.2020.00371
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MYCN amplification and ATRX mutations are incompatible in neuroblastoma
- (2020) Maged Zeineldin et al. Nature Communications
- Role of Y-family Translesion DNA Polymerases in Replication Stress: Implications for New Cancer Therapeutic Targets
- (2019) Peter Tonzi et al. DNA REPAIR
- Homologous recombination and the repair of DNA double-strand breaks
- (2018) William Douglass Wright et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors
- (2018) Marialaura Petroni et al. Cell Death & Disease
- Talazoparib: First Global Approval
- (2018) Sheridan M. Hoy DRUGS
- ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells
- (2017) Stephanie A. Yazinski et al. GENES & DEVELOPMENT
- Oncogene-Induced Replication Stress Drives Genome Instability and Tumorigenesis
- (2017) Dan Sarni et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor
- (2017) Masatoshi Takagi et al. JNCI-Journal of the National Cancer Institute
- 11q deletion in neuroblastoma: a review of biological and clinical implications
- (2017) Vid Mlakar et al. Molecular Cancer
- The essential kinase ATR: ensuring faithful duplication of a challenging genome
- (2017) Joshua C. Saldivar et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma
- (2017) V Colicchia et al. ONCOGENE
- Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program
- (2017) Raushan T. Kurmasheva et al. PEDIATRIC BLOOD & CANCER
- The Devil is in the details for DNA mismatch repair
- (2017) Peggy Hsieh et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Current status of poly(ADP-ribose) polymerase inhibitors and future directions
- (2017) Akihiro Ohmoto et al. OncoTargets and Therapy
- Alternative NHEJ pathway proteins as components of MYCN oncogenic activity in human neural crest stem cell differentiation: implications for neuroblastoma initiation
- (2017) Erika A. Newman et al. Cell Death & Disease
- Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials
- (2017) Jian Xin Zhou et al. Drug Design Development and Therapy
- Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor
- (2017) Masatoshi Takagi et al. JNCI-Journal of the National Cancer Institute
- Targeting the ATR-CHK1 Axis in Cancer Therapy
- (2017) Stuart Rundle et al. Cancers
- An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma
- (2016) Donna L. Nile et al. BMC CANCER
- Factors associated with recurrence and survival length following relapse in patients with neuroblastoma
- (2016) Nermine O Basta et al. BRITISH JOURNAL OF CANCER
- Telomere biology including TERT rearrangements in neuroblastoma: a useful indicator for surgical treatments
- (2016) Masumi Kawashima et al. JOURNAL OF PEDIATRIC SURGERY
- ATM Mutations in Cancer: Therapeutic Implications
- (2016) M. Choi et al. MOLECULAR CANCER THERAPEUTICS
- DNA repair targeted therapy: The past or future of cancer treatment?
- (2016) Navnath S. Gavande et al. PHARMACOLOGY & THERAPEUTICS
- Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer
- (2016) Anika Maria Weber et al. Oncotarget
- Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
- (2016) Junko Murai et al. Oncotarget
- Neuroblastoma
- (2016) Katherine K. Matthay et al. Nature Reviews Disease Primers
- Cancer Cells with Alternative Lengthening of Telomeres Do Not Display a General Hypersensitivity to ATR Inhibition
- (2016) Katharina I. Deeg et al. Frontiers in Oncology
- Myc induced replicative stress response: How to cope with it and exploit it
- (2015) Sara Rohban et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- Tumor suppressor p53 and its mutants in cancer metabolism
- (2015) Juan Liu et al. CANCER LETTERS
- Abstract LB-210: Telomerase activation by genomic rearrangements in high-risk neuroblastoma
- (2015) Martin Peifer et al. CANCER RESEARCH
- Telomere maintenance is pivotal for high-risk neuroblastoma
- (2015) Falk Hertwig et al. CELL CYCLE
- The MRN complex is transcriptionally regulated by MYCN during neural cell proliferation to control replication stress
- (2015) M Petroni et al. CELL DEATH AND DIFFERENTIATION
- Molecular Pathways: Targeting ATR in Cancer Therapy
- (2015) L. M. Karnitz et al. CLINICAL CANCER RESEARCH
- Nucleotide excision repair in humans
- (2015) Graciela Spivak DNA REPAIR
- The same, only different - DNA damage checkpoints and their reversal throughout the cell cycle
- (2015) I. A. Shaltiel et al. JOURNAL OF CELL SCIENCE
- Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
- (2015) Thomas F Eleveld et al. NATURE GENETICS
- TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors
- (2015) Linda J Valentijn et al. NATURE GENETICS
- ATM and ATR as therapeutic targets in cancer
- (2015) Anika Maria Weber et al. PHARMACOLOGY & THERAPEUTICS
- Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors
- (2015) R. L. Flynn et al. SCIENCE
- ATRX represses alternative lengthening of telomeres
- (2015) Christine E. Napier et al. Oncotarget
- The Mechanism by Which MYCN Amplification Confers an Enhanced Sensitivity to a PCNA-Derived Cell Permeable Peptide in Neuroblastoma Cells
- (2015) Long Gu et al. EBioMedicine
- The regulation of MDM2 oncogene and its impact on human cancers
- (2014) Y. Zhao et al. ACTA BIOCHIMICA ET BIOPHYSICA SINICA
- Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification
- (2014) R Defferrari et al. BRITISH JOURNAL OF CANCER
- ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma
- (2014) Scott C. Bresler et al. CANCER CELL
- Dynamic expression ofN-mycin mouse embryonic development using an enhanced green fluorescent protein reporter gene in theN-myclocus
- (2014) Ming Ma et al. DEVELOPMENT GROWTH & DIFFERENTIATION
- Crosstalk between the nucleotide excision repair and Fanconi anemia/BRCA pathways
- (2014) Kent W. Mouw et al. DNA REPAIR
- Identification and Pharmacological Inactivation of the MYCN Gene Network as a Therapeutic Strategy for Neuroblastic Tumor Cells
- (2014) Olesya Chayka et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Emergence of New ALK Mutations at Relapse of Neuroblastoma
- (2014) Gudrun Schleiermacher et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a Pediatric Brain Tumor Consortium report†
- (2014) Jack M. Su et al. NEURO-ONCOLOGY
- Replication stress links structural and numerical cancer chromosomal instability
- (2013) Rebecca A. Burrell et al. NATURE
- Causes and consequences of replication stress
- (2013) Michelle K. Zeman et al. NATURE CELL BIOLOGY
- The genetic landscape of high-risk neuroblastoma
- (2013) Trevor J Pugh et al. NATURE GENETICS
- Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors
- (2013) Robin E. Norris et al. PEDIATRIC BLOOD & CANCER
- Focal DNA Copy Number Changes in Neuroblastoma Target MYCN Regulated Genes
- (2013) Candy Kumps et al. PLoS One
- The chromatin remodeller ATRX: a repeat offender in human disease
- (2013) David Clynes et al. TRENDS IN BIOCHEMICAL SCIENCES
- DNA Damage Sensing by the ATM and ATR Kinases
- (2013) A. Marechal et al. Cold Spring Harbor Perspectives in Biology
- Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project
- (2012) G Schleiermacher et al. BRITISH JOURNAL OF CANCER
- The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma
- (2012) Teeara Berry et al. CANCER CELL
- Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis
- (2012) Shizhen Zhu et al. CANCER CELL
- Combination Therapy Targeting the Chk1 and Wee1 Kinases Shows Therapeutic Efficacy in Neuroblastoma
- (2012) M. R. Russell et al. CANCER RESEARCH
- Association of Age at Diagnosis and Genetic Mutations in Patients With Neuroblastoma
- (2012) Nai-Kong V. Cheung JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Chk’ing p53-deficient breast cancers
- (2012) David W. Schoppy et al. JOURNAL OF CLINICAL INVESTIGATION
- Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes
- (2012) Jan J. Molenaar et al. NATURE
- Children's Oncology Group's 2013 blueprint for research: Neuroblastoma
- (2012) Julie R. Park et al. PEDIATRIC BLOOD & CANCER
- Loss of Wild-Type ATRX Expression in Somatic Cell Hybrids Segregates with Activation of Alternative Lengthening of Telomeres
- (2012) Kylie Bower et al. PLoS One
- Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification
- (2012) L. J. Valentijn et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Neuroblastoma
- (2012) Andrew M. Davidoff Seminars in Pediatric Surgery
- p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance
- (2012) Lindi Chen et al. Frontiers in Oncology
- Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)
- (2011) G Schleiermacher et al. BRITISH JOURNAL OF CANCER
- Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines
- (2011) A Peasland et al. BRITISH JOURNAL OF CANCER
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Fas death receptor signalling: roles of Bid and XIAP
- (2011) T Kaufmann et al. CELL DEATH AND DIFFERENTIATION
- Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
- (2011) Philip M Reaper et al. Nature Chemical Biology
- Survival and late effects in children with stage 4 neuroblastoma
- (2011) Thomas Perwein et al. PEDIATRIC BLOOD & CANCER
- RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma
- (2011) K. A. Cole et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Emerging importance of ALK in neuroblastoma
- (2011) Anna M. Azarova et al. SEMINARS IN CANCER BIOLOGY
- The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo
- (2010) V. J. Weston et al. BLOOD
- p53 Is a Direct Transcriptional Target of MYCN in Neuroblastoma
- (2010) L. Chen et al. CANCER RESEARCH
- High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma
- (2010) J. Carr-Wilkinson et al. CLINICAL CANCER RESEARCH
- The ARF tumor suppressor: Structure, functions and status in cancer
- (2010) Peggy Ozenne et al. INTERNATIONAL JOURNAL OF CANCER
- Checkpoint kinase inhibitor synergizes with DNA-damaging agents in G1checkpoint-defective neuroblastoma
- (2010) Hong Xu et al. INTERNATIONAL JOURNAL OF CANCER
- Recent Advances in Neuroblastoma
- (2010) John M. Maris NEW ENGLAND JOURNAL OF MEDICINE
- ATM is down-regulated by N-Myc-regulated microRNA-421
- (2010) H. Hu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Repair of ionizing radiation-induced DNA double-strand breaks by non-homologous end-joining
- (2009) Brandi L. Mahaney et al. BIOCHEMICAL JOURNAL
- Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma
- (2009) R. A. Daniel et al. CLINICAL CANCER RESEARCH
- Telomere biology in neuroblastoma: telomere binding proteins and alternative strengthening of telomeres
- (2009) Yoshiyuki Onitake et al. JOURNAL OF PEDIATRIC SURGERY
- High incidence of DNA mutations and gene amplifications of theALKgene in advanced sporadic neuroblastoma tumours
- (2008) Helena Carén et al. BIOCHEMICAL JOURNAL
- A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor
- (2008) Nicholas C Turner et al. EMBO JOURNAL
- Myc's broad reach
- (2008) M. Eilers et al. GENES & DEVELOPMENT
- The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report
- (2008) Susan L. Cohn et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of ALK as a major familial neuroblastoma predisposition gene
- (2008) Yaël P. Mossé et al. NATURE
- Activating mutations in ALK provide a therapeutic target in neuroblastoma
- (2008) Rani E. George et al. NATURE
- Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
- (2008) Isabelle Janoueix-Lerosey et al. NATURE
- Single-strand break repair and genetic disease
- (2008) Keith W. Caldecott NATURE REVIEWS GENETICS
- High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma
- (2008) E. Fredlund et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas
- (2008) Frank Westermann et al. GENOME BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now